Gem Aromatics Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Gem Aromatics Ltd trades at ₹186, in a downtrend and 47 weeks into that stage. That is −4.3% against its own 200-day average. It sits at 30% of a 52-week range of ₹141 to ₹290. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.

Today the stock is in a downtrend — week 47 of stage 4, confirmed. At ₹186 it trades −4.3% versus its 200-day average and sits at 30% of its 52-week range (₹141–₹290).

Against the market, two honest reads. Cumulative: over the last 11 months the stock moved −33% while the NIFTY 500 moved +2% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 100th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Gem Aromatics Ltd trades at 651.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 23.9×, measured across 0.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 651.0× is about the priciest it has ever traded, against a long-run median of 23.9× measured over 0.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved −97.6% against a −32.7% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Gem Aromatics Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

30.1/100 — rank 17 of 20 in Chemicals - Organic · 60% evidence confidence

Gem Aromatics Ltd scores 30.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 17. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 2.7 + 8.9 + 8.5 + 10 = 30.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Gem Aromatics Ltd reported ₹110 Cr of revenue in the Mar 26 quarter, −45.4% year on year. Over 5 years it has compounded at 3.6% a year. The last full year, FY26, came in at ₹366 Cr. The last four reported quarters add to ₹366 Cr.

Gem Aromatics Ltd reported ₹110 Cr of revenue in the Mar 26 quarter, −45.4% year on year. Over 5 years it has compounded at 3.6% a year. The last full year, FY26, came in at ₹366 Cr. The last four reported quarters add to ₹366 Cr.

FY26 revenue came in at ₹366 Cr (−27.4% on the year), capping 5 years at 3.6% compound. The latest quarter (Mar 26) printed ₹110 Cr, −45.4% year on year.

Pace check: the last four quarters averaged −22.4% growth against the decade's 3.6% — the current year is running slower than its own long-run rate.

→ Revenue slipped — did margins hold as it scaled? Next: 14.2% this quarter (−8.4 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Gem Aromatics Ltd's operating margin is 14.2% in the Mar 26 quarter, −8.4 percentage points against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 10.0% to 18.0%. The current quarter sits inside that band.

Gem Aromatics Ltd's operating margin is 14.2% in the Mar 26 quarter, −8.4 percentage points against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 10.0% to 18.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 14.2%, −8.4 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 10.0%–18.0%.

🚨 Why the margin moved: operating margin went −8.4 pp year on year while gross margin went +3.7 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins slipped — did that reach the bottom line? Next: profit −96.3% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Gem Aromatics Ltd earned ₹1.0 Cr of net profit in the Mar 26 quarter, −96.3% year on year. Full-year FY26 profit was ₹1.0 Cr. The 5-year compound rate is −46.6%. That is 0.9% of the quarter's revenue. The same quarter a year earlier earned ₹27.6 Cr. 2 of the last 8 reported quarters were loss-making.

Gem Aromatics Ltd earned ₹1.0 Cr of net profit in the Mar 26 quarter, −96.3% year on year. Full-year FY26 profit was ₹1.0 Cr. The 5-year compound rate is −46.6%. That is 0.9% of the quarter's revenue. The same quarter a year earlier earned ₹27.6 Cr. 2 of the last 8 reported quarters were loss-making.

Mar 26 profit was ₹1.0 Cr, −96.3% year on year. On the full year, FY26 printed ₹1.0 Cr (−98.1%), and the 5-year compound rate is −46.6%.

🚨 Why profit moved: revenue contributed −45.4% and the margin −8.4 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −99.2% vs revenue −22.4%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 43% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 43% of Gem Aromatics Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹30.0 Cr of operating cash against ₹1.0 Cr of profit. After ₹102 Cr of capital spending, ₹−72.0 Cr was left as free cash.

FY26: operating cash of ₹30.0 Cr against reported profit of ₹1.0 Cr, leaving free cash of ₹−72.0 Cr after ₹102 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 43% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at 43%: the cash cycle stretched 200 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 200 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 360-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Gem Aromatics Ltd's cash conversion cycle runs 360 days in FY26, up from 160 days in FY21. Capital spending ran ₹248 Cr over the last 3 years. At FY26 sales of ₹366 Cr each day of that cycle holds about ₹1.0 Cr, so roughly ₹361 Cr sits inside the business at any moment.

FY26: debtors at 76 days, inventory at 309 days — roughly 10.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 360 days, looser than FY21's 160.

The full loop: cash goes out to suppliers and production on day 0; stock waits 309 days to sell; customers pay about 76 days after that; and suppliers themselves are paid at 25 days — netting out to the 360-day cycle.

In money terms: at FY26 sales of ₹366 Cr, each day of the cycle holds about ₹1.0 Cr — so the 360-day loop keeps roughly ₹361 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹248 Cr over the last 3 fiscal years against ₹36.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹6.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 3% and the ROIC − WACC spread is −11.3 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Gem Aromatics Ltd earns a ROCE of 3% in FY26. Return on invested capital clears the cost of that capital by −11.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.3% net margin on 0.57× asset turns.

FY26 ROCE is 3%.

🚨 Why the return is what it is — the wiring (FY26): 0.3% net margin × 0.57× asset turns × 1.43× balance-sheet leverage ≈ 0.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 0.7% − 12.0% = a −11.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.34.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Gem Aromatics Ltd carries total debt of ₹152 Cr against shareholder equity of ₹450 Cr as of Mar 26, a debt-to-equity of 0.34. On the annual view that ratio went from 0.79 in FY25 to 0.34 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹152 Cr against shareholder equity of ₹450 Cr — a debt-to-equity of 0.34. On the annual view, debt-to-equity went from 0.79 (FY25) to 0.34 (FY26). Read the returns on this page with that leverage in mind.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Gem Aromatics Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — .

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Gem Aromatics Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions